EIKON THERAPEUTICS INC reported that FMR LLC beneficially owned 3,836,830 shares of Common Stock, representing 7.1% of the class as of 03/31/2026. The filing lists FMR LLC's sole dispositive power over 3,836,830 shares and discloses that other persons may have rights to dividends or sale proceeds but no other person holds more than 5%.
The report was signed under power of attorney and references an attached 13d-1(k) agreement in Exhibit 99.
Positive
None.
Negative
None.
Insights
FMR LLC holds a >5% stake in Eikon, disclosed via Schedule 13G.
FMR LLC reports beneficial ownership of 3,836,830 shares, equal to 7.1% of the common stock as of 03/31/2026. The filing identifies sole dispositive power for FMR LLC and lists shared voting power as zero.
Institutional holdings above 5.0 are routinely disclosed; this confirms a material passive stake under Schedule 13G reporting. Subsequent filings will show any change in passive/active status or stake size.
Disclosure clarifies control attributes and a referenced 13d-1(k) arrangement.
The schedule states FMR LLC has sole dispositive power for 3,836,830 shares and indicates other persons may have rights to dividends or proceeds, with none exceeding 5.0%. The report is executed under a power of attorney.
Exhibit 99 and the cited power of attorney are the filings to consult for the precise subsidiary/agent relationships and any special allocation rules.
Key Figures
Beneficial ownership:3,836,830 sharesPercent of class:7.1%Reporting date:03/31/2026+1 more
4 metrics
Beneficial ownership3,836,830 sharesAmount beneficially owned as stated in Item 4
Percent of class7.1%Percent of common stock as reported
Reporting date03/31/2026Date referenced at top of the filing
CUSIP282564103CUSIP number for Common Stock
Key Terms
Schedule 13G, Beneficially owned, Sole dispositive power, 13d-1(k) agreement
4 terms
Schedule 13Gregulatory
"Item 1 shows the filing is a Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially ownedfinancial
"Item 4(a) states Amount beneficially owned: 3836830.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole dispositive powerfinancial
"Item 4(iii) shows Sole power to dispose: 3836830.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
13d-1(k) agreementregulatory
"Exhibit Information references Exhibit 99 for 13d-1(k) agreement"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
EIKON THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
282564103
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,835,530.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,836,830.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,836,830.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,836,830.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,836,830.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
EIKON THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
230 HARRIET TUBMAN WAY,MILLBRAE,CA,USA,94030
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP Number(s):
282564103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3836830.00
(b)
Percent of class:
7.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
3836830.00
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of EIKON THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of EIKON THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Richard Bourgelas
Name/Title:
Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
05/05/2026
Abigail P. Johnson
Signature:
Richard Bourgelas
Name/Title:
Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:
05/05/2026
Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.
FMR LLC reports beneficial ownership of 3,836,830 shares, representing 7.1% of EIKON's common stock as of 03/31/2026. This holding is disclosed on a Schedule 13G filing.
Does the filing say who controls voting or sale decisions for these EIKON shares?
The filing states FMR LLC has sole dispositive power over 3,836,830 shares and lists shared voting power as zero. It notes other persons may have rights to dividends or proceeds, with none over 5%.
Is this Schedule 13G an active or passive ownership disclosure for EIKON?
The document is a Schedule 13G disclosure showing a substantial ownership position. It does not on its face reclassify the position as active; the filing format indicates passive reporting consistent with institutional holdings above 5%.
What exhibits or documents accompany the filing that clarify relationships?
The filing references a power of attorney effective April 13, 2026, and an attached 13d-1(k) agreement in Exhibit 99. Those exhibits describe authority and subsidiary relationships referenced in the schedule.
Who signed the Schedule 13G for FMR LLC on the EIKON filing?
The filing is signed by Richard Bourgelas as duly authorized under a power of attorney, and cites Abigail P. Johnson in the cover-page information tied to FMR LLC's reporting.
